Clinical Trial Update: Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial update from Northwestern University evaluating the combination of epcoritamab and lenalidomide in patients with refractory or relapsed B-cell no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Polymorphic Post-transplant Lymphoproliferative Disorder
• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• EPKINLY (EPCORITAMAB-BYSP)
• Revlimid (lenalidomide)

Snippet

Sponsor: Northwestern University | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | Status: ACTIVE_NOT_RECRUITING